公开(公告)号：EP1943337B1

公开(公告)日：2015-07-15

申请号：EP06832470.6

申请日：2006-11-02

申请人： Educational Foundation Jichi Medical University ,  OTSUKA PHARMACEUTICAL CO., LTD.

发明人： YOSHIDA, Shigeto ,  SUDO, Toshiki

IPC分类号： C12N15/12 ,  C07K14/435 ,  A61K38/17 ,  G01N33/50

CPC分类号： C07K14/43563 ,  A61K38/17 ,  G01N33/5088

公开(公告)号：EP1943337A1

公开(公告)日：2008-07-16

申请号：EP06832470.6

申请日：2006-11-02

申请人： Educational Foundation Jichi Medical University ,  OTSUKA PHARMACEUTICAL CO., LTD.

发明人： YOSHIDA, Shigeto ,  SUDO, Toshiki

IPC分类号： C12N15/00 ,  A61K38/00 ,  A61P7/02 ,  C07K14/435 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50

CPC分类号： C07K14/43563 ,  A61K38/17 ,  G01N33/5088

摘要： The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.

公开(公告)号：EP4389128A1

公开(公告)日：2024-06-26

申请号：EP22858550.1

申请日：2022-08-19

申请人： Otsuka Pharmaceutical Co., Ltd.

发明人： SONE, Masayuki ,  MATSUYAMA, Hironori ,  TAZURU, Keisuke ,  KOGUE, Yosuke ,  AKAMINE, Hiroki ,  SUDO, Toshiki

IPC分类号： A61K31/5377 ,  A61K35/17 ,  A61P35/00 ,  A61P43/00

CPC分类号： A61P43/00 ,  A61K31/5377 ,  A61P35/00 ,  A61K39/4632 ,  A61K39/464488 ,  A61K39/464412 ,  A61K39/4611 ,  A61K2239/3120230501 ,  A61K39/4613 ,  A61K39/4631

摘要： The present invention discloses administering pharmaceutical compositions in combination, one of which is a pharmaceutical composition containing a tolinapant drug, and the other of which is a pharmaceutical composition containing an immune cell modified to express a chimeric antigen receptor or a recombinant T-cell receptor.